BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 14, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Revlimid lenalidomide: Additional Phase III data

Additional data from 370 evaluable patients in a Phase III trial showed that following induction treatment with Revlimid plus low-dose dexamethasone resulted in at least a partial response (PR) in 86% of patients and at least a very good partial response (VGPR) in 37%. After randomization, 55% of patients who received >=3 cycles of maintenance therapy with Revlimid plus...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >